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Abstract
Background: Human group A rotavirus is the leading cause of severe acute gastroenteritis in young children
worldwide. Immunization programs have reduced the disease burden in many countries. Vaccination coverage in
the Autonomous Region of Valencia, Spain, is around 40%, as the rotavirus vaccine is not funded by the National
Health System. Despite this low-medium vaccine coverage, rotavirus vaccination has substantially reduced
hospitalizations due to rotavirus infection and hospital-related costs. However, there are very few studies evaluating
symptomatic rotavirus infections not requiring hospitalization in vaccinated children. The objective of this study was to
investigate symptomatic rotavirus infections among vaccinated children in the health area served by the Hospital Clínico
Universitario of Valencia, Spain, from 2013 to 2015.
Methods: A total of 133 children younger than 5 years of age with rotavirus infection were studied. Demographic and
epidemiological data were collected and informed consent from their caretakers obtained. Rotavirus infection was
detected by immunological methods and G/P rotavirus genotypes were determined by RT-PCR, following standard
procedures from the EuroRotaNet network.
Results: Forty infants (30.1%; 95% CI: 22.3–37.9) out of 133 were diagnosed with symptomatic rotavirus infection despite
having been previously vaccinated, either with RotaTeq (85%) or with Rotarix (15%). Children fully vaccinated against
rotavirus (24.8%), partially vaccinated (5.3%) and unvaccinated (69.9%) were found. The infecting genotypes showed high
G-type diversity, although no significant differences were found between the G/P genotypes infecting vaccinated and
unvaccinated children during the same time period. G9P[8], G12P[8] and G1P[8] were the most prevalent genotypes.
Severity of gastroenteritis symptoms required 28 (66.6%) vaccinated and 67 (73.6%) unvaccinated children to be
attended at the Emergency Room.
Conclusion: Rotavirus vaccine efficacy in reducing the incidence of severe rotavirus infection has been well
documented, but symptomatic rotavirus infection can sometimes occur in vaccinees.
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Background
Group A rotaviruses are the leading cause of acute
gastroenteritis in infants and young children worldwide.
At 5 years of age almost every child has suffered at least
one rotavirus infection [1]. Moreover, the same child is
likely to become infected several times during the first
years of life, although the symptomatology of the second
infection is usually milder and the third is typically
asymptomatic [2]. In adults, rotavirus infection is usually
asymptomatic or mild, although it can be severe in im-
munocompromised individuals or the elderly [3]. Both
infected children and adults shed rotaviruses in their
stools, causing the virus to spread easily within the com-
munity [4]. Rotavirus is also an major cause of nosoco-
mial diarrhoea [5].
In the years prior to the introduction of rotavirus vac-
cines, this virus was responsible for 440,000 deaths per
year [6]. According to the most recent study of the glo-
bal burden of disease, rotavirus infection was responsible
in 2016 for an estimated 128,500 deaths (95% uncer-
tainty interval [UI],104,500 - 155,600) among children
younger than 5 years; thus, 28.8% (95% UI, 25.0–32.6%)
of the deaths from diarrhea in this age group were at-
tributable to rotavirus [7]. In developing countries al-
most all these deaths are due to dehydration and related
to poor health care [1]. In developed countries mortality
is very low, but rotavirus infection is the main cause of
child hospitalization due to acute gastroenteritis (2 mil-
lion hospitalizations each year) and is responsible for 25
million outpatient consultations each year worldwide
[8]. In Spain, mortality due to rotavirus is almost non-
existent; however, rotavirus is responsible for 14 to 30%
of all cases of acute gastroenteritis and of these, a quar-
ter require hospitalization [9]. Rotavirus acute gastro-
enteritis costs the Spanish National Health System
around 28 million euros per year [10].
Since 2006 two live attenuated oral rotavirus vaccines
have been marketed worldwide: the monovalent Rotarix®
(GSK Biologicals, Rixensart, Belgium), an attenuated hu-
man G1P[8] vaccine, and the pentavalent bovine-human
mono-reassortant RotaTeq® vaccine (Merck and Co, PA,
USA), which contains human rotavirus VP4 (P[8]) and
VP7 (G1-G4) genes in a bovine rotavirus genetic back-
ground [11]. The two vaccines have been highly effective
in industrialized countries [12, 13], but studies carried
out in sub-Saharan African countries showed far lower
efficacy in these geographical areas [14, 15]. WHO rec-
ommends the inclusion of rotavirus vaccine in the Na-
tional Childhood Immunization Program in countries
with high incidence of rotavirus infection [16]. Their im-
plementation in many countries has demonstrated a re-
duction in the disease burden of rotavirus diarrhoea and
related death in several geographic regions worldwide
[17–20] including sub-Saharan African countries [21].
Rotavirus vaccines are also recommended by the Spanish
Paediatric Association since 2008 [22], but they are not
funded by the National Health System. In Spain, parents
pay for the vaccine, and vaccination coverage has
reached around 40% in the Autonomous Region of Val-
encia [23]. Despite this low-medium vaccine coverage,
the introduction of rotavirus vaccines has had a specific
coverage-related impact on hospitalizations due to acute
gastroenteritis in children under 5 years of age, and their
use has substantially reduced hospital-related costs [24].
After rotavirus vaccine implementation, the prevalence
of rotavirus diarrhoea in children has changed [25–27],
but there are few studies evaluating symptomatic infec-
tions not requiring hospitalization in vaccinated children
[28, 29]. The purpose of this study was to investigate the
presence of symptomatic rotavirus infections among vac-
cinated infants and children in the city of Valencia,
Spain between January 2013 and December 2015.
Methods
Study population and sample collection
The study was carried out with paediatric patients from
the health area of the Hospital Clínico Universitario of
Valencia. The total population attended by this hospital
is 345,498, of whom 20,091 (5.82%) are children under 5
years of age. In the Autonomous Region of Valencia
rotavirus vaccination is not included in the Childhood
Vaccination Programme, and its use is restricted to pri-
vate healthcare or to the initiative of parents and
guardians.
The study protocol and the informed consent given by
caretakers of the children included in the study was ap-
proved by the Clinical Research Ethics Committee of the
Hospital Clínico Universitario of Valencia (Approval No.
F-CE-GEva-15) and by the Juvenile Prosecutor’s Office
of Valencia (ref. 33/15).
During the first study phase data were collected be-
tween January 2013 and December 2015 from a total of
217 patients with acute gastroenteritis due to rotavirus,
who were attended either at the Primary Care Paediat-
rics Clinics served by the Hospital Clínico Universitario
of Valencia or at the Paediatrics Emergency Room of the
same hospital. Once the data had been collected, the
children’s parents or caregivers were requested permis-
sion to enrol them in the study, which was obtained for
133 children. Of these, 71 patients (53.4%) were inhabi-
tants of the metropolitan area of Valencia and 62 pa-
tients (46.6%) were from rural areas served by the
Hospital Clínico Universitario of Valencia.
In order to make a comparative analysis we included a
control group of 50 healthy children, 24 boys (48%;
CI95%: 33.7–62.6) and 26 girls (52%; CI95%: 37.4–66.3),
with similar demographic characteristics to the patient
group. Age at time of analysis ranged from 1month to 5
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years, with an average of 2 years and 10months; 31
(62%) were under 3 years of age. Concerning rotavirus
vaccination, 28 children (56%; CI95%: 41.3–70) had been
vaccinated.
Detection of rotavirus in stool samples
Detection of rotavirus antigen in stool samples was per-
formed by an immunochromatographic test (Rotavirus-
Adenovirus, Certest Biotec, Spain) (in 173 samples,
79.7%) or by ELISA (Premier™ Rotaclone, Meridian Bio-
science, Cincinnati, OH, US) (in 44 samples, 20.3%) fol-
lowing the manufacturer’s instructions. The sensitivity
and specificity of the Premier™ Rotaclone® assay have
been reported to be 76.8 and 100% compared to an RT-
PCR assay, respectivey [30], whereas the sensitivity and
specificity of the CerTest Rotavirus+Adenovirus ICG test
for detection of rotavirus are 99 and 98%, respectively,
compared with a commercial ELISA test (Ridascreen®Ro-
tavirus, R-Biopharm, Germany) and according to the
manufacturer.
Diagnosis of other enteric pathogens
To investigate possible concomitant enteropathogenic
bacteria, stool samples were plated onto bacterial culture
media, including selenite broth, MacConkey agar, Salmon-
ella Shigella agar, cefsulodin-irgasan-novobiocin agar,
charcoal cefoperazone deoxycholate agar (CCDA) and
Columbia agar with 5% sheep blood. All culture media
were from BD Diagnostics (Heidelberg, Germany). All the
specimens were processed immediately upon arrival at the
laboratory. Culture media were incubated at 37 °C for 24
h, except CCDA plates, which were incubated at 42 °C
under microaerophilic conditions for 48 h. Colonies con-
sidered as presumptive enteric pathogens were identified
with matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF MS Biotyper 3.1,
Bruker, MA, US). Other enteric viruses like astroviruses
were investigated using ProSpecT Astrovirus Microplate
EIA Assay from Oxoid (Thermo Fisher Scientific, MA,
US) according to the manufacturer’s instructions, and
noroviruses by RT-PCR as previously described [31].
Characterization of rotavirus G and P genotypes
Rotavirus-positive samples were confirmed by RT-PCR
and the infecting rotavirus genotypes were identified.
Faecal suspensions at 10–20% (w/v) were prepared in
phosphate buffered saline (PBS) pH 7.2. Viral RNA was
extracted by the guanidine isothiocyanate and silica
matrix method (Boom method) [32] or by extraction
with Trizol® (Invitrogen) [33]. The extracted RNA was
kept at − 80 °C until processed by reverse transcription
and PCR.
The reverse transcription reaction was performed with
random primers using SuperScript® III reverse transcriptase
(Life Technologies, Thermo Fisher Scientific, MA, US). The
encoding genes of rotavirus proteins VP7 and VP4 were
amplified in two different PCR reactions. Subsequently,
‘multiplex’ PCR reactions were used to identify the geno-
type G (VP7) and P (VP4) of each rotavirus strain, following
previously procedures described [34] and standardized by
the European Rotavirus Surveillance Network, “EuroRota-
Net” (www.eurorotanet.com).
Statistical analysis
Data were analysed using the R Core Team 2015 soft-
ware (version 3.2.2). The estimated frequency was calcu-
lated as a percentage with a 95% confidence interval for
each variable. To compare them, Chi-square test was
used, except in cases in when the frequency was less
than 5, in which Fisher’s exact test was applied. Signifi-
cant differences were assumed for p values < 0.05. The
results obtained for each of the variables were compared
using the median-unbiased estimation method. For this
purpose, the first category of each variable was taken as
a reference and compared to the remaining categories
analysed for the same variable [35].
Results
Demographic and clinical features of the study
population
Patient ages ranged from 13 days to 5 years, average 22
months. Most children (112, 84.2%) were under 3 years of
age, 62 were female (46.6%; CI95%: 37.9–55.5) and 71
were male (53.4%; CI95%: 44.5–62.1). Regarding rotavirus
vaccination status, 93 patients (69.92%; CI95%: 62.1–77.7)
had not received any vaccine dose at the time of infection
(Fig. 1). Twenty-eight (66.6%) vaccinated children and 67
(73.6%) unvaccinated children were attended at the Paedi-
atric Emergency Room due to severity of symptoms.
Infecting rotavirus genotypes
Most patients (90.2%) were infected by a single rotavirus
genotype and in those with mixed infections (7.5%) two
different genotypes were detected (Fig. 2). The most fre-
quently found P genotype was P[8] (97.7%; CI95%: 93.5–
99.5) and only two patients were infected by a P[4]
genotype (1.5%; CI95%: 0.2–5.3). Regarding G genotype,
G1, G2, G3, G4, G9 and G12 were detected. Temporary
distribution of rotavirus G genotypes along the study
period is shown in Fig. 3. The predominant G/P geno-
type was rotavirus G9P[8] (49.6%; CI95%: 40.8–58.4),
followed by G1P[8] (20.3%; CI95%: 13.8–28.1) and
G12P[8] (14.3%; CI95%: 8.8–21.4). Peak infection periods
occurred during the coldest months of the year (Novem-
ber to April), with G9P[8] genotype being the most
prevalent during these months in the 2013–14 and
2014–15 seasons. In 2013, in addition to the winter peak,
there was an increase in rotavirus infections from March
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Fig. 1 Distribution by age and rotavirus vaccination status of children. Highest vaccine coverage occurs in children under 3 years of age. The
vaccinated group includes full (33) and partially (7) vaccinated children
Fig. 2 Distribution of rotavirus G/P genotypes. Ninety-eight percent of the rotavirus strains detected corresponded to the P[8] genotype,
predominantly the G9[P8] genotype
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to July due to the G1P[8] genotype. The number of
G1P[8] genotype infections remained stable for most of
the study period, with minimal oscillations during seasons.
Although rotavirus infections were detected from June to
December 2015, the caretakers of those patients did not
sign informed consent to participate in the study.
Rotavirus G/P genotypes detected in vaccinated children
Forty infants (30.1%; CI95%: 22.3–37.9) out of the 133 di-
agnosed with rotavirus infection had been previously vac-
cinated. Of these, 33 had been fully vaccinated, whereas 7
children received an incomplete number of vaccine doses.
The infecting genotypes showed high G genotype diversity
(Table 1), although no significant differences were found
between the G/P genotypes infecting vaccinated and un-
vaccinated children (p = 0.706) (Table 2). Twenty-eight
(66.6%) vaccinated children and 67 (73.6%) unvaccinated
children were attended at the Paediatric Emergency Room
due to severity of symptoms.
Detection of other enteric pathogens
None of other investigated enteropathogenic bacteria or vi-
ruses (enteric adenoviruses, astroviruses and noroviruses)
were detected in these patients by conventional methods.
Relationship between rotavirus infection and vaccination
status
In our study, 30.1% (CI95%: 22.3–37.9) of rotavirus-
infected patients had been previously vaccinated with
one of the two vaccines marketed in Spain. The propor-
tion of vaccinated children in the group of patients with
rotavirus infection was lower than in the control group
of uninfected children (OR: 2.96; CI95%: 1.51–5.78;
p = 0.003) (Table 3). This is an interesting finding and
supports the need for vaccination.
Table 4 shows the ages of the vaccinated children when
they suffered rotavirus diarrhoea, the type of vaccine
Fig. 3 Temporary distribution of G genotypes of infecting rotavirus. Significant variations were observed in the incidence of rotavirus infection as
well as in the relative frequency of the G genotypes detected during the study
Table 1 Distribution of rotavirus G/P genotypes in 40









G1P[8] + G9P[8] 2 (5)
G3P[8] + G9P[8] 2 (5)
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administered (monovalent Rotarix or pentavalent Rota-
Teq), the ages in weeks when doses were given, the time
frame between last vaccine dose and infection, and the in-
fecting rotavirus genotype. Four children were infected
with rotavirus G9P[8] less than 2months after the first
vaccine dose. Because this genotype is not present in the
composition of the vaccines faecal shedding of vaccine
strains can be excluded. Another child was infected with
rotavirus G9P[8] 5 days after having received the last dose.
Discussion
Throughout the study period, the incidence of rotavirus
infections fluctuated significantly both in number of
cases and prevalence of different infecting G genotypes,
as was expected in a temperate climate region [36].
Both rotavirus vaccines currently marketed, Rotarix®
and RotaTeq®, have demonstrated very good safety and ef-
ficacy in large clinical trials, providing protection against
homotypic and heterotypic rotavirus strains [12–14, 37].
However, the present study has revealed symptomatic
rotavirus infections among fully vaccinated children.
Rotavirus vaccine coverage in our geographical area
has been estimated at 42% [23]. A minimum single dose
can be viewed as affording protection, because a previ-
ous study in our Autonomous Region have shown high
protection with partial vaccination [23]. Nevertheless, 7
out of our patients had only received a single vaccine
dose, 6 with RotaTeq and 1 with Rotarix. This would
imply that partial vaccination does not protect ad-
equately. Higher levels of vaccination among children
under 3 years of age was observed; however, it was pre-
cisely this age group that experienced the greatest num-
ber of infections. The ratio of vaccinated children
among rotavirus-infected patients (30.1%) was lower
than in the control group (56%) (OR: 2.96, CI95%: 1.51–
5.78, p = 0.003). It has been claimed that high percent-
ages of rotavirus detection by immunochromatographic
method in vaccinated children, could be due to false
positives, especially when the test is performed outside
rotavirus seasons [38]. However, all the positive results
reported in this study were confirmed by RT-PCR, and
the infecting rotavirus strains were characterized. It has
been reported that vaccinated children may shed vaccine
strains in stool samples up to 13 days post vaccination
[39]. However, infecting rotavirus genotypes in the chil-
dren reported in this study are not present in the com-
position of the vaccines, except G1P[8], or the time
frame between last dose and time of infection exceeded
potential faecal shedding of vaccine strains in immuno-
competent patients [40]. Although none of other investi-
gated enteropathogenic bacteria or viruses were detected
in our patients by conventional methods, we cannot
completely exclude that more sensitive molecular
methods could have detected some coinfection.
Current rotavirus vaccines were designed according to
the circulating strains in the 1980s, when G1, G2, G3,
G4, P[4] and P[8] were the most prevalent genotypes
and G1P[8] was the dominant rotavirus in most Western
countries [41, 42]. However, circulating rotaviruses are
currently different, having diversified thanks to their
evolutionary mechanisms and to genotype fluctuations
[43]. In a study conducted in Belgium, significant anti-
genic differences were demonstrated between the G1
and P[8] components present in vaccine strains and in
circulating G1P[8] strains [44]. In addition, a study car-
ried out in Nashville (USA) indicates that the antigenic
Table 2 Rotavirus genotypes in vaccinated and unvaccinated children
Rotavirus Genotype Vaccinated a
(n = 44) (%)
Unvaccinated b




G1P[8] 8c (18.2) 26f (26.6) – –
G2P[4] 0 – 2 (2) 1.60 (0.07–36.80) 0.768
G3P[8] 2d (5) 5g (5.1) 0.77 (0.12–4.75) 0.777
G4P[8] 2 (5) 3 (3) 0.46 (0.06–3.27) 0.439
G9P[8] 24e (54.6) 47h (48) 0.60 (0.24–1.53) 0.287
G12P[8] 8 (18.2) 12i (12.3) 0.46 (0.14–1.52) 0.205
ND 0 – 3 (3) 2.24 (0.10–48) 0.605
ND Not determined
a7 patients were partially vaccinated: one patient vaccinated with 1 dose of Rotarix© and 6 patients vaccinated with 1 dose of RotaTeq©
bIn 3 patients it was not possible to determine the infecting genotype
c2 in mixed infection / d 2 in mixed infection / e 4 in mixed infection / f 5 in mixed infection / g 5 in mixed infection / h 3 in mixed infection / i 1 in mixed infection
Table 3 Comparison of the ratio of vaccinated and
unvaccinated children among rotavirus-infected patients and
healthy controls. The data analysis shows a greater tendency of
unvaccinated individuals to contract rotavirus infection. The




Patients Controls Odds ratio p value
(n = 133) (%) (n = 50) (%) (CI 95%)
Unvaccinated 93 (69.92) 22 (44.00) – –
Vaccinated 40 (30.08) 28 (56.00) 2.96 (1.51–5.78) 0.003
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Table 4 Features of the rotavirus infections in vaccinated children (age at time of infection, type of vaccine and doses given, time
frame between last vaccine dose and infection, and infecting viral genotypes)














Years Months Years Months
1 1 9 Rotarix® 8 16 NA 1 5 G1P[8]
2 4 9 RotaTeq® 8 Not given Not given 4 7 G9P[8]
3 0 4 RotaTeq® 8 Not given Not given 0 2 G9P[8]
4 3 2 RotaTeq® 8 16 24 2 8 G9P[8]
5 1 8 RotaTeq® 8 17 25 1 1 G9P[8]
6 1 9 RotaTeq® 9 15 24 1 3 G9P[8]
7 4 3 RotaTeq® 8 16 23 3 9 G9P[8]
8 0 4 RotaTeq® 7 Not given Not given 0 1 G9P[8]
9 1 10 RotaTeq® 8 16 24 1 4 G9P[8]
10 1 6 RotaTeq® 8 17 23 1 0 G12P[8]
11 2 10 RotaTeq® 9 17 25 2 4 G9P[8]
12 0 10 RotaTeq® 8 16 24 0 4 G12P[8]
13 0 8 RotaTeq® 9 Not given Not given 0 6 G12P[8]
14 2 0 RotaTeq® 8 17 25 1 5 G9P[8]
15 1 6 RotaTeq® 10 16 24 1 0 G4P[8]
16 0 11 RotaTeq® 8 16 24 0 5 G12P[8]
17 1 7 RotaTeq® 8 16 24 1 1 G9P[8]
18 1 8 RotaTeq® 12 18 24 1 2 G9P[8]
19 1 7 RotaTeq® 8 16 24 1 1 G9P[8]
20 0 6 RotaTeq® 7 20 27 0 7 G1P[8]
21 1 3 RotaTeq® 8 16 25 0 9 G9P[8]
22 2 7 RotaTeq® 8 17 24 2 1 G12P[8]
23 4 4 Rotarix® 9 17 NA 3 11 G12P[8]
24 0 7 RotaTeq® 9 Not given Not given 0 5 G9P[8]
25 4 11 Rotarix® 10 17 NA 4 6 G9P[8]
26 1 5 RotaTeq® 9 17 25 0 11 G3 + G9P[8]
27 1 2 RotaTeq® 8 16 25 0 8 G12P[8]
28 3 1 RotaTeq® 8 16 24 2 6 G12P[8]
29 2 7 RotaTeq® 9 16 24 2 1 G9P[8]
30 0 9 RotaTeq® 10 17 25 0 3 G3 + G9P[8]
31 1 1 Rotarix® 8 16 NA 0 10 G1 + G9P[8]
32 1 8 RotaTeq® 9 17 25 1 2 G1P[8]
33 1 8 RotaTeq® 8 16 23 1 3 G9P[8]
34 1 7 RotaTeq® 8 16 24 1 1 G1P[8]
35 5 10 Rotarix® 12 Not given NA 5 7 G1P[8]
36 1 4 RotaTeq® 7 16 23 0 11 G1 + G9P[8]
37 0 3 RotaTeq® 8 Not given Not given 0 1 G9P[8]
38 2 8 RotaTeq® 9 16 24 2 2 G1P[8]
39 1 1 Rotarix® 12 23 NA 0 7 G4P[8]
40 0 6 RotaTeq® 9 17 25 0 0 G9P[8]
NA Not applicable
Not given doses denote partially vaccinated children
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differences observed between circulating rotavirus and
vaccine strains are greater in G9P[8] and G12P[8] than in
other genotypes [45]. This fact could reduce selective
pressure from neutralizing antibodies in these genotypes,
which would explain their global epidemiological increase.
Furthermore, the effects of widespread vaccination on
rotavirus evolution and the level of cross-protection pro-
vided by current vaccines against antigenically distinct ro-
taviruses remain areas of active investigation [45]. In this
study, G9P[8], G12P[8] and G1P[8] were the most fre-
quently detected genotypes in vaccinated children, as well
as in the unvaccinated population. Interestingly, a marked
increase of rotavirus G12P[8] in the hospital setting was
reported in Nicaragua, associated with a nationwide pre-
dominance of this genotype in a population with high
pentavalent vaccine coverage [46]. It could be considered
that some factors might cause a selection or rotavirus
strains circulating in the area, and perhaps vaccination
could be one of them. In addition, several host factors
have been suggested to impact on the protection induced
by rotavirus vaccines in children, like breastfeeding, the
presence or absence of immune and non-immune compo-
nents in breast milk and the intestinal bacterial microbiota
[47, 48]. Recent studies show that histo-blood group anti-
gens, complex carbohydrates located on the surface of
mucosa epithelial cells, play a role in human rotavirus in-
fections [49, 50]. Moreover, the use of rotavirus vaccines
may give rise to unexpected consequences, as it has been
found that circulating atypical rotavirus strains can origin-
ate via reassortment between human G1P[8] and RotaTeq
vaccine strains [51]. Pitzer et al. performed a mathematical
model to understand the potential impact of vaccination
on genotype distributions which suggested that vaccin-
ation may influence the selection of the different circulat-
ing genotypes [52]. Another study data to corroborate this
assertion was inconclusive [43]. Nevertheless, despite
some antigenic changes in circulating genotypes, the vac-
cine showed dramatic effect and reduction in rotavirus
diarrhea [52]. In all likelihood, the selection of the circu-
lating rotavirus genotypes that we have observed in this
work is more complex, perhaps owing to a set of circum-
stances that encompass natural evolution, vaccination and
other unknown factors. The effects of vaccination on the
circulating rotavirus strains are probably more complex
than merely serotype selection. Nevertheless, additional
monitoring and directed studies will help to clarify the
specific roles of vaccines in rotavirus selection and
evolution.
Conclusions
Rotavirus vaccine failures may cause loss of confidence
in the vaccine and lower the estimates of vaccine effect-
iveness. Although the impact of rotavirus vaccines on
various commonly circulating strains has been well
documented, with a drastic reduction in morbidity and
mortality worldwide, rotavirus infections can sometimes
occur, especially in populations with low and moderate
vaccination coverage. Further studies are needed to ex-
plain possible vaccine failures and to clarify the specific
role of vaccines in rotavirus selection and evolution.
Despite rotavirus vaccination, paediatricians should con-
sider rotavirus as a suspected agent in cases of acute
gastroenteritis.
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